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Abstract
Previous studies reported disruption of adenylyl cyclase (AC)^cyclic AMP (cAMP) signal transduction in brain of
Alzheimer’s disease (AD). We also demonstrated that basal and stimulated AC activities in the presence of calcium and
calmodulin (Ca2/CaM) were significantly decreased in AD parietal cortex. In the present study, we examined the amounts
of Ca2/CaM-sensitive types I and VIII AC, and Ca2/CaM-insensitive type VII AC in the postmortem hippocampi from
AD patients and age-matched controls using immunoblotting. The specificities of the anti-type VII and VIII AC antibodies
were confirmed by preabsorption with their specific blocking peptides. We observed a significant decrease in the level of type
I AC and a tendency to decrease in the level of type VIII AC in AD hippocampus. On the other hand, the level of type VII
AC showed no alteration between AD and controls. A body of evidence from the studies with invertebrates and vertebrates
suggests that types I and VIII AC may play an essential role in learning and memory. Our finding thus firstly demonstrated
that a specific disruption of the Ca2/CaM-sensitive AC isoforms is likely involved in the pathophysiology in AD
hippocampus. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The intact intracellular signal transduction from
postsynaptic receptor to an e¡ector system is re-
quired for the maintenance of neuronal activity and
e⁄cient interneuronal communication. The response
of the e¡ector system depends on the type of neuro-
transmitter receptor activated and can result in the
opening of ion channels or the modulation of e¡ector
enzymes, such as adenylyl cyclase (AC).
Disruptions in the AC complex are well recognized
to exist in Alzheimer’s disease (AD) [1]. It has been
reported that Gs protein-mediated activation of AC
is decreased in the neocortex and cerebellum in AD
subjects [2]. Reduced basal and stimulated AC activ-
ities have also been observed in the AD hippocampus
and cerebellum [3,4].
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AC catalyzes the formation of cyclic AMP
(cAMP), an important second messenger for protein
phosphorylation and ion-channel gating [5]. This en-
zyme is regulated by a wide range of neurotransmit-
ter receptors, as well as by intracellular free calcium
and its binding protein, calmodulin. To date, nine
mammalian AC subtypes (types I^IX AC) have
been cloned, and they show di¡erent biochemical
features and tissue distributions [6^8] (Table 1).
Although all of the isoforms are expressed in neural
tissue, types I and VIII AC are expressed exclusively
in brain, whereas the other isoforms are expressed
also in non-neural tissues [6,7,9]. Type I, type III,
and type VIII AC can be stimulated by calcium
and calmodulin (Ca2/CaM) [6,10,11], but the other
types are inhibited by this combination (types V and
VI AC) [12] or insensitive to it (types II, IV, and VII)
[13].
Our previous studies reported decreased levels of
types I and II AC in AD parietal cortex and also
showed decreased basal and stimulated (forskolin
and manganese) AC activities in the presence of
Ca2/CaM in the same brain region of AD [14,15].
These ¢ndings indicate that speci¢c changes in the
catalytic subunits of Ca2/CaM-sensitive AC iso-
forms may be involved in pathophysiology of AD.
There is now growing evidence that types I and VIII
AC likely play an important role in construction of
some aspects of learning and memory in mammali-
ans [16,17]. Moreover, we have also reported de-
creased immunoreactivity of the phosphorylated
form of cAMP response element binding protein
(CREB) in AD hippocampus [18], suggesting the
possibility that a widely impaired cAMP signal trans-
duction including dysregulation of gene transcription
might occur in AD brain.
The aim of the present study is to determine
whether Ca2/CaM-sensitive type I and type VIII
AC are impaired in AD hippocampus, which shows
severe AD pathology, and to provide additional evi-
dence on the role of cAMP as a functional molecule
in human brain. We have thus investigated immuno-
reactivities of types I and VIII AC in hippocampal
membranes from AD patients and age-matched con-
trols using immunoblotting. Moreover, Ca2/CaM-
insensitive type VII AC isoform was also examined
Table 1
Mammalian adenylyl cyclases
Type Tissue distributiona E¡ect of Ca2/CaM
I Brain Stimulation
VIII Brain Stimulation
III Olfactory epithelium Stimulation
II Ubiquitous No e¡ect (insensitive)
IV Ubiquitous No e¡ect (insensitive)
VII Ubiquitous No e¡ect (insensitive)
V Heart, brain Inhibition
VI Heart, brain Inhibition
IX Ubiquitous Unknown
aFor details of tissue distribution, see [6^8].
Table 2
Subjects’ characteristics
Control Sex Age (years) PMDT (h) Cause of death AD Sex Age (years) PMDT (h) Cause of death
C1 Female 86 72.0 Ovarial carcinoma A1 Male 85 56.0 Pneumonia
C2 Male 66 35.0 Myocardial infarction A2 Female 79 47.0 Pneumonia
C3 Female 90 24.0 Heart failure A3 Female 81 25.0 Sepsis
C4 Male 86 29.0 Myocardial infarction A4 Female 94 27.0 Pneumonia
C5 Female 71 29.3 Hepatocell carcinoma A5 Male 63 72.0 Heart failure
C6 Male 61 18.0 Myocardial infarction A6 Female 82 16.0 Pulmonary embolism
C7 Female 71 10.0 Sepsis A7 Female 72 34.0 Pneumonia
C8 Female 84 24.0 Myocardial infarction A8 Male 87 4.0 Heart failure
C9 Female 80 5.0 Lung carcinoma A9 Male 81 19.0 Pneumonia
C10 Male 73 54.0 Myocardial infarction A10 Female 78 24.0 Pneumonia
C11 Female 71 17.0 Pneumonia A11 Male 72 8.0 Pneumonia
There were no signi¢cant di¡erences in age (mean þ S.E.M. 76.27 þ 2.84 in control, 79.45 þ 2.51 in AD) and postmortem delay time
(PMDT) (mean þ S.E.M. 28.85 þ 5.85 in control, 30.18 þ 6.25 in AD) between controls and AD patients.
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to compare with the two Ca2/CaM-sensitive AC
subtypes. Reliabilities of polyclonal antibodies
against types VII and VIII AC were con¢rmed by
preabsorption with blocking peptides as we previ-
ously performed with anti-type I AC antibody.
2. Materials and methods
2.1. Human postmortem brain tissues
Hippocampal membranes were obtained from 11
AD patients and 11 age-matched controls with no
neuropsychiatric disorders. AD was diagnosed in ac-
cordance with NINCDS-ADRDA criteria [19]. De-
tailed characteristics of patients and controls are pre-
sented in Table 2. The procedure used for
acquisition, clinical diagnosis, dissection, storage,
and distribution of brain materials in our brain
bank system was previously described in detail [20].
2.2. Preparation of membranes and protein
measurement
The brain tissues were homogenized in a bu¡er
containing 20 mM Hepes, 0.25 M sucrose, 0.3 mM
PMSF, 1 mM DTT, 1 mM EGTA, and 1 mM
MgCl2 (pH 7.4), and centrifuged at 600Ug for
10 min. The supernatants were centrifuged at
48 000Ug for 20 min. The pellets were then resus-
pended in a bu¡er containing 20 mM Hepes, 0.3
mM PMSF, and 1 mM DTT (pH 7.4), and centri-
fuged in the same way. The membrane-enriched pel-
lets were resuspended in the same bu¡er and stored
at 380‡C until use.
Protein concentrations were determined by the
Coomassie blue binding method using bovine serum
albumin (BSA) as a standard [21].
2.3. Gel electrophoresis and immunoblotting of
AC isoforms
The hippocampal membranes were separated by
sodium dodecyl sulfate^polyacrylamide gel electro-
phoresis (SDS^PAGE) and electrophoretically trans-
ferred to nitrocellulose membranes for subsequent
immunoblotting as previously described [14,15]. For
detection of type I AC, 20 Wg of protein was used
and for detection of types VII and VIII AC, 30 Wg of
protein was needed. In brief, membranes were sub-
jected to SDS^PAGE with 4^12% polyacrylamide
gels at 125 V for 2 h. Proteins were transferred to
nitrocellulose membranes at 30 V for 75 min at room
temperature. The membranes were blocked in TBS-T
bu¡er (10 mM Tris, 500 mM NaCl, 0.1% Tween-20,
pH 7.5) containing 5% BSA for 1 h at room temper-
ature and then incubated in TBS-T bu¡er containing
3% BSA overnight at 4‡C with primary antibodies
diluted 1:1000 in anti-type I AC: sc-586 and anti-
VIII AC: sc-1967, and 1:2500 in anti-type VII AC:
sc-1966 (Santa Cruz Biotechnology, CA, USA).
Membranes were washed and incubated with second-
ary antibodies, anti-rabbit Ig HRP-linked F(abP)2
(Amersham Life Science, UK) diluted to 1:2500 for
type I AC and HRP-conjugated anti-goat IgG (H
and L) (Rockland, PA, USA) diluted to 1:4000 for
types VII and VIII AC, in 3% BSA/TBS bu¡er for 1 h
at room temperature.
2.4. Preabsorption of type VII and type VIII
AC antibodies
Speci¢c blocking peptides against anti-type VII
and VIII AC antibody (sc-1966P and sc-1967P; San-
ta Cruz Biotechnology) were added to primary anti-
body solution in concentrations of 0.01^1 Wg peptide
Wl31, respectively [14]. The mixture was incubated
overnight at 4‡C with rocking, then centrifuged at
3000 rpm for 30 min at room temperature. Immuno-
blotting was then performed with the recovered
supernatant as the primary antibody solution.
2.5. Densitometric measurement of immunoreactivities
and statistical analysis
Immunoreactive bands were detected with the en-
hanced chemiluminescence (ECL) system (Amer-
sham) and analyzed by laser densitometry (NIH
1.55 image analysis system).
Results are given as the means þ S.E.M. The data
were analyzed by Welch’s t-test and values of
P6 0.01 were taken to indicate statistical signi¢cance
of di¡erence between groups. The e¡ects of age and
postmortem interval on each immunoreactivity were
determined by Spearman’s rank order correlation
analysis.
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3. Results
3.1. Linearity of immunoblots of types I, VII, and
VIII AC in human hippocampal membrane
Linearity of our immunoblots was tested using
control human hippocampal membrane. In the im-
munoblots using this standard membrane, the densi-
tometric values were in proportion to protein
amounts loaded on to the gel within the limits 5^50
Wg for type I AC and 5^75 Wg for types VII and VIII
AC (data not shown). Therefore, we decided that the
optimal protein amounts for immunoblottings were
20 Wg for type I AC and 30 Wg for types VII and VIII
AC, respectively, and the identical control membrane
preparation was routinely used as a standard to en-
sure that the analysis of the samples was performed
within the linear range of the method.
3.2. E¡ects of age and postmortem delay time on
AC subtypes in human hippocampus
We previously demonstrated that age and post-
mortem delay time (PMDT) did not in£uence the
immunoreactivity of type I AC in human cortical
membrane [14]. Similarly, we examined the e¡ects
of age and PMDT on immunoreactivities of types
I, VII, and VIII AC in human hippocampal mem-
branes with Spearman’s rank order analysis using all
Fig. 1. Results of immunoblots of types VII and VIII AC with
anti-type VII and VIII AC antibodies and after preabsorption
of the antibodies with each speci¢c blocking peptide. Lane 1:
no peptide was applied. Lanes 2^5: 0.01, 0.1, 0.5, and 1.0 Wg
peptide Wl31 of primary antibody solution, respectively. Molecu-
lar mass markers are indicated at the left margin of each panel.
Fig. 2. E¡ects of the dose of speci¢c blocking peptides on the immunoreactivities of anti-type VII AC (a) and type VIII AC (b) anti-
bodies in the preabsorption study. An equal amount of total protein (30 Wg) of control human hippocampal membrane was used for
each immunoblot. The immunoreactivity and the amount of applied peptide shows a biphasic linear relation.
BBADIS 61997 29-11-00
M. Yamamoto et al. / Biochimica et Biophysica Acta 1535 (2000) 60^68 63
subjects. Neither age nor PMDT had a signi¢cant
e¡ect on the measured immunoreactivities of the
AC isoforms in controls (Ps 0.10 in all cases). There
were also no signi¢cant correlations between age or
PMDT and immunoreactivities of the three subtypes
in AD subjects (Ps 0.14 in all cases).
3.3. E¡ect of preabsorption of the type VII and VIII
AC antibodies on the immunoreactivity
Fig. 1 shows the preabsorption study of anti-type
VII AC antibody and anti-type VIII AC antibody
using control human standard membrane. Preab-
sorption of the antibodies with their speci¢c blocking
peptides diminished or completely abolished the im-
munoreactivities of each AC isoform and the elimi-
nations occurred in a biphasic linear relation, with
one phase between 0 and 0.01 Wg/Wl of added peptide
and a second one between 0.01 and 1.0 Wg/Wl of
competing peptide (Fig. 2).
3.4. Protein levels of AC isoforms in the postmortem
hippocampus of AD patients
Representative immunoblots of the type I, VII,
and VIII AC isoforms in hippocampus from AD
subjects and controls are presented in Fig. 3. Immu-
noreactive bands of each AC subtype migrated at the
expected molecular mass range (120^130 kDa) [5].
The anti-type I AC antibody reacted with the protein
band that was detected at an apparent molecular
mass of 120 kDa. We have previously demonstrated
by immunoblotting and preabsorption of the anti-
body with the speci¢c blocking peptide that the 120
kDa protein is type I AC [14,22].
Fig. 4 depicts data obtained by densitometric anal-
ysis of all results obtained from 11 AD patients and
11 controls. Immunoreactivity of Ca2/CaM-sensi-
tive type I AC was signi¢cantly decreased to 40.1%
of control levels (P6 0.01) in the AD hippocampus.
A moderate reduction of Ca2/CaM-sensitive type
VIII AC immunoreactivity was observed in AD sub-
jects; however, that did not reach signi¢cance. In
contrast, immunoreactivity of type VII AC, which
is a Ca2/CaM-insensitive subtype, was not altered
between AD and controls.
4. Discussion
As factors which might a¡ect the detection of im-
munoreactivities of AC isoforms, we examined the
Fig. 3. Representative immunoblots of type I, VII, and VIII
AC isoforms in human hippocampal membranes (A, AD; C,
control). Molecular mass markers are indicated at the left mar-
gin of each panel.
Fig. 4. Results of densitometric analysis of immunoreactivities
of three AC isoforms. Data are expressed as mean ( þ S.E.M.)
percentage of control human standard membrane. *P6 0.01
was accepted as the level for statistical signi¢cance by Welch’s
t-test.
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e¡ects of age and PMDT on each AC subtype. The
absence of correlations between the immunoreactivi-
ty of each AC isoform and age or PMDT in the
present study argues against a confounding in£uence
of aging and postmortem e¡ect on the obtained ob-
servations.
In the preabsorption study of anti-type VII AC
antibody and anti-type VIII AC antibody with their
respective complementary peptides, each antibody re-
acted with its speci¢c blocking peptide and the im-
mune complex formed was removed as a pellet by
centrifugation. The reaction between antibody and
its blocking peptide occurred in a biphasic linear
manner and thus the speci¢c immunoreactive band
completely disappeared when a high dose of the pep-
tide was applied. These results con¢rmed the specif-
icity and reliability of the antibodies used.
Impaired signal transduction could occur as a re-
sult of alterations in neurotransmitter receptor levels,
receptor/G-protein coupling, G-protein levels, G-
protein/e¡ector enzyme coupling, e¡ector enzyme
levels, or due to actions of intracellular second mes-
sengers. Previous studies demonstrated that the AC
signal transduction pathway is disrupted at a number
of these components in AD brain.
It was reported that Gs-protein-stimulated AC ac-
tivity is decreased in AD frontal, temporal, and oc-
cipital cortices, as well as angular gyrus and cerebel-
lum, while basal and forskolin-stimulated activities
showed no alteration [2]. Another study from the
same group also showed a speci¢c impairment of
Gs-protein-stimulated AC activity in AD hippocam-
pus [23]. These ¢ndings suggest that there is a speci¢c
lesion in AD brain at the level of Gs-protein^AC
interactions. On the other hand, it was shown that
basal, forskolin-stimulated AC activities, as well as
Gs-protein-stimulated activity, are decreased in AD
hippocampus and cerebellum [3,4], indicating that
both the Gs protein and catalytic subunit of AC
are impaired in AD brain. The discrepancy between
these studies may be re£ected by di¡erences in the
AC assay conditions, i.e., presence or absence of
Ca2/CaM. In this respect, we have previously mea-
sured AC activity in both the presence and absence
of Ca2/CaM and reported that basal, forskolin-,
and Mn2-stimulated AC activities in the presence
of Ca2/CaM are decreased in AD parietal cortex,
whilst AC activities assayed without Ca2/CaM show
no signi¢cant alteration in the disease [15]. This sug-
gests that Ca2/CaM-sensitive AC isoforms may play
a critical role in altered AC signal transduction in
AD brain. Indeed, we have seen that Ca2/CaM-sen-
sitive and neuronal speci¢c type I AC is signi¢cantly
reduced in AD parietal cortex [14,15].
In the present study, we examined protein levels of
type I, VII, and VIII AC isoforms in the hippocam-
pus of 11 AD patients and 11 control subjects using
immunoblotting and observed a signi¢cant decrease
in the immunoreactivity of type I AC in AD patients.
Accordingly, we assume this alteration to be a com-
mon lesion in the brain a¡ected by the disease. On
the other hand, we observed a tendency to decreased
immunoreactivity of type VIII AC and no signi¢cant
alteration in the level of type VII AC in AD hippo-
campus. Thus, immunoreactivities of the three AC
isoforms were not consistently altered, indicating
that expression of each AC subtype might be di¡er-
ently regulated in AD hippocampus. The alterations
of types I and VIII AC observed in the present study
might have been a consequence of the neuronal loss
seen in AD a¡ected brain. However, we cannot sim-
ply explain the decrease and tendency to decrease of
these AC isoforms by the e¡ect of change in neuro-
nal density in this brain region, since the amount of
type VII AC, which is also contained in synaptic
membranes, was not altered.
Mammalian AC isoforms are expressed in all tis-
sues, but at very low levels, approximately 0.01^
0.001% of membrane protein [7]. Types I and VIII
AC show prominent expression in neurons, particu-
larly in regions of the brain associated with learning
and memory [9,24]. In rat brains, the strongest
mRNA signals of these subtypes are found in the
hippocampus, and moderate levels of both mRNAs
are detected in the neocortex and other regions. Type
VII AC is distributed among a number of tissues,
including brain, heart, kidney, and liver. In brain,
type VII mRNA is primarily expressed in the cere-
bellar granule cell layer [25]. Interestingly, we have
found changes only in the levels of the type I and
VIII AC isoforms in AD which show dominant lo-
calizations within the hippocampus, indicating that
these two subtypes may be important molecules in
mediating the functions of hippocampal neurons. Fu-
ture investigations concerning mRNA expressions of
AC isoforms in human brain regions including AD
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brain will be strongly expected to address the molec-
ular mechanism of the alteration observed.
We have previously demonstrated decrease in the
level of phosphorylated form of cAMP-response ele-
ment binding protein (CREB) in AD hippocampus
[18], which is a transcription factor in the down-
stream AC^cAMP signaling system [26]. The present
study includes seven AD and seven control cases,
which are same subjects used in our previous study
on CREB proteins [18]. Concerning these samples,
we have examined correlations between the reported
immunoreactivity of phosphorylated or total CREB
[18] and the present immunoreactivity of each AC
isoform, respectively. There were no signi¢cant cor-
relations between the phosphorylated or total CREB
immunoreactivity and the immunoreactivities of
three AC subtypes in AD subjects, as well as in con-
trols (data not shown). The lack of signi¢cant corre-
lation between the phosphorylated CREB and the
type I and type VIII AC suggests that the decrease
in the level of phosphorylated CREB reported in AD
hippocampus may not be induced directly by the
disruption of these AC subtypes. Phosphorylation
of Ser133 is crucial for transcriptional activation of
CREB and this is catalyzed not only by protein ki-
nase A (PKA) but also by Ca2-activated calmodulin
kinases, ribosomal S6 kinase 2, and mitogen-acti-
vated protein kinase-activated protein kinase 2 [27].
It might be possible that disruptions of these other
enzymes occur in AD hippocampus and reveal the
decreased amount of the phosphorylated CREB.
Evidence from the studies with neuronal systems
of invertebrate, as well as with mammalian brain,
suggest that Ca2/CaM-sensitive AC isoforms may
be important for learning and memory [17,28]. Fur-
thermore, activation of the AC^cAMP signaling sys-
tem, including PKA and CREB, may play an essen-
tial role in regulation of gene transcription and
synthesis of speci¢c proteins required for long-term
synaptic changes [29,30]. It was observed that some
forms of long-term potentiation (LTP), which is at
present supposed to be a model for long-term mem-
ory formation in the brain, elevate cAMP levels in
the hippocampus [31]. Animal studies have demon-
strated that the functional knock-out of type I AC or
CREB by transgenic techniques or speci¢c antisense
oligodeoxynucleotides results in impaired formation
of long-term memory, whereas enhancement of the
AC subtype or the transcription factor accelerates
the process [16,29,32,33]. AC^cAMP signaling and
CREB-dependent transcription thus appear essential
for long-term memory consolidation in animals.
However, there was little information to address
the molecular mechanisms of learning and memory
in the human brain. Our previous and present obser-
vations provide the ¢rst evidence that the Ca2/
CaM-sensitive AC isoforms, especially type I AC,
may contribute to formation of long-term memory
in the human brain.
In most cases of AD, the brain regions including
the cholinergic basal forebrain complex, the locus
ceruleus, the median raphe nuclei, and hippocampus
show severe neurodegenerative changes [34,35].
Therefore, it is strongly suggested that the speci¢c
disruptions of the Ca2/CaM-sensitive AC subtypes
found in the present study in AD hippocampi may
be involved in the pathophysiology of AD, and pos-
sibly become manifest as the impaired memory con-
solidation observed in the disease.
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